Journal article
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development
M Bialer, SI Johannessen, MJ Koepp, RH Levy, E Perucca, P Perucca, T Tomson, HS White
Epilepsia | WILEY | Published : 2020
DOI: 10.1111/epi.16725
Abstract
Since 1992, the Eilat Conferences have provided a forum for all stakeholders in the epilepsy community to appraise the latest data on new antiepileptic drugs and emergency seizure treatments, including, in recent years, updates on progress with the development of novel monitoring and therapeutic devices. Because of the COVID-19 pandemic, the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV) was held as a fully virtual conference on July 27-30, 2020 for the sessions on drugs and on August 3, 2020 for the sessions on devices, and was attended during the 5 days by >500 participants from 63 countries. This progress report summarizes key preclinical and initial (phase 1..
View full abstractGrants
Awarded by Epilepsy Foundation
Funding Acknowledgements
We wish to thank the authors of the summary sections for their patience in addressing the queries raised during the review process, and for their collaboration with the final editing of the manuscript. The work described in the GAO-3-02 section, to which all summary authors contributed equally, was supported by a grant from the technology transfer office PULSALYS. The authors of the same summary also wish to thank Victor Blot, Melodie Borel, and Beatrice Georges for their technical support.